Clinical Trial

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Study acronym: PLATEAU
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the effect of enobosarm on total body weight
Protocol Amendment History 2 changes
notable Trial sites expanded: 10 -> 14 locations 2026-07-01
notable Trial sites expanded: 7 -> 10 locations 2026-04-23
Trial Details
NCT Number NCT07446998
Lead Sponsor Veru Inc.
Conditions Obesity & Overweight, Mobility Disability, HOMA-IR
Enrollment 200 participants
Start Date 2026-03-26
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-01